Miscellaneous diagnostic tests:
Indications for: SPHERUSOL
To detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.
Limitations of Use:
Use in patients with unknown exposure to C. immitis is not evaluated. Patients with acute or disseminate coccidioidomycosis, immunodeficiency and history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol.
Adult Dosage:
Give by intradermal inj. 18–64yrs: 0.1mL to the volar surface of forearm. Assess for induration at 48±4hrs after administration. Mean induration ≥5mm: positive for delayed-type hypersensitivity response.
Children Dosage:
<18yrs: not established.
Boxed Warning:
Larger accelerated reactions may occur. Systemic reactions; may be life-threatening or fatal. Not for IV inj.
SPHERUSOL Warnings/Precautions:
Review medical history for skin test sensitivity and related adverse reactions. Have trained personnel and medical equipment readily available. Monitor for ≥30mins post inj for adverse reactions. Immunosuppression. Infection. Elderly. Pregnancy (Cat.C). Nursing mothers.
SPHERUSOL Classification:
Antigen test.
SPHERUSOL Interactions:
Concomitant beta-blockers may antagonize epinephrine inj. Concomitant corticosteroids and immunosuppressants may suppress response to the skin test.
Adverse Reactions:
Itching, swelling, pain; anaphylactic reactions.
Generic Drug Availability:
NO
How Supplied:
Multi-dose vial (1mL)—1
